---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-030403"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:31:22.175910+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Esperion monetizes European bempedoic acid royalties for $304.7M, pays off Oberland facility

## Summary
- Received $304.7M from OMERS in exchange for 100% of European bempedoic acid royalty until OMERS receives 1.7x investment (≈$518M), then royalties revert to Esperion.
- Used proceeds to early payoff and termination of Oberland Capital revenue interest facility for $343.75M cash, removing senior secured liens.
- Esperion retains potential future commercial milestones from DSE of up to $300M based on net sales thresholds.
- Royalty to OMERS is tiered 15-25% of DSE net sales; Esperion regains full royalty stream after cap is reached.
- CFO Ben Halladay cited enhanced balance sheet and increased operational flexibility to focus on U.S. commercialization.

## SEC filing metadata
- accession: 0001628280-24-030403
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828024030403/0001628280-24-030403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828024030403/espr-20240627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-030403
- JSON: https://secwatch.observer/filing/0001628280-24-030403.json
- Plain text: https://secwatch.observer/filing/0001628280-24-030403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.